ロード中...
Chronic myelogenous leukemia on target
Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro‐leukemic activity of the BCR‐ABL1 oncoprotein. Despite the therapeutic progress mediated by TKI use, off‐target effects, treatment‐induced drug resistance, and the limited effect of the...
保存先:
| 出版年: | Cancer Med |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6051163/ https://ncbi.nlm.nih.gov/pubmed/29905026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1604 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|